BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 20071119)

  • 1. Quantitative multivoxel proton chemical shift imaging of the breast.
    Sijens PE; Dorrius MD; Kappert P; Baron P; Pijnappel RM; Oudkerk M
    Magn Reson Imaging; 2010 Apr; 28(3):314-9. PubMed ID: 20071119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: an initial experience.
    Hsieh TJ; Li CW; Chuang HY; Liu GC; Wang CK
    J Comput Assist Tomogr; 2008; 32(6):987-94. PubMed ID: 19204465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton magnetic resonance spectroscopy of musculoskeletal lesions at 3 T with metabolite quantification.
    Lee CW; Lee JH; Kim DH; Min HS; Park BK; Cho HS; Kang HG; Suh JS; Ehara S
    Clin Imaging; 2010; 34(1):47-52. PubMed ID: 20122519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters.
    Sitter B; Lundgren S; Bathen TF; Halgunset J; Fjosne HE; Gribbestad IS
    NMR Biomed; 2006 Feb; 19(1):30-40. PubMed ID: 16229059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive evaluation of cerebral glioma grade by using multivoxel 3D proton MR spectroscopy.
    Zeng Q; Liu H; Zhang K; Li C; Zhou G
    Magn Reson Imaging; 2011 Jan; 29(1):25-31. PubMed ID: 20832225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy.
    Sardanelli F; Fausto A; Di Leo G; de Nijs R; Vorbuchner M; Podo F
    AJR Am J Roentgenol; 2009 Jun; 192(6):1608-17. PubMed ID: 19457825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrast/Noise ratio on conventional MRI and choline/creatine ratio on proton MRI spectroscopy accurately discriminate low-grade from high-grade cerebral gliomas.
    Fayed N; Morales H; Modrego PJ; Pina MA
    Acad Radiol; 2006 Jun; 13(6):728-37. PubMed ID: 16679275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary study of 3T 1H MR spectroscopy in bone and soft tissue tumors.
    Qi ZH; Li CF; Li ZF; Zhang K; Wang Q; Yu DX
    Chin Med J (Engl); 2009 Jan; 122(1):39-43. PubMed ID: 19187615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of single voxel 1H MR spectroscopy of bone tumors: differentiation of benign from malignant tumors.
    Zhang J; Cheng K; Ding Y; Liang W; Ding Y; Vanel D; Cheng X
    Eur J Radiol; 2013 Dec; 82(12):2124-8. PubMed ID: 22169357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-COSY of breast cancer at 3T.
    Ramadan S; Baltzer PA; Lin A; Stanwell P; Box H; Kaiser WA; Mountford CE
    Eur J Radiol; 2012 Sep; 81 Suppl 1():S129-31. PubMed ID: 23083559
    [No Abstract]   [Full Text] [Related]  

  • 11. In vivo proton magnetic resonance spectroscopy of breast lesions: an update.
    Tse GM; Yeung DK; King AD; Cheung HS; Yang WT
    Breast Cancer Res Treat; 2007 Sep; 104(3):249-55. PubMed ID: 17051424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined DCE-MRI and single-voxel 2D MRS for differentiation between benign and malignant breast lesions.
    Lipnick S; Liu X; Sayre J; Bassett LW; Debruhl N; Thomas MA
    NMR Biomed; 2010 Oct; 23(8):922-30. PubMed ID: 20878970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of choline concentration in breast lesions: quantitative multivoxel proton MR spectroscopy as a promising noninvasive assessment tool to exclude benign lesions.
    Dorrius MD; Pijnappel RM; Jansen-van der Weide MC; Jansen L; Kappert P; Oudkerk M; Sijens PE
    Radiology; 2011 Jun; 259(3):695-703. PubMed ID: 21460033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1H-MRSI of prostate cancer: the relationship between metabolite ratio and tumor proliferation.
    Wang XZ; Wang B; Gao ZQ; Liu JG; Liu ZQ; Niu QL; Sun ZK; Yuan YX
    Eur J Radiol; 2010 Feb; 73(2):345-51. PubMed ID: 19070978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of musculoskeletal lesions on 3-T proton MR spectroscopy.
    Fayad LM; Barker PB; Jacobs MA; Eng J; Weber KL; Kulesza P; Bluemke DA
    AJR Am J Roentgenol; 2007 Jun; 188(6):1513-20. PubMed ID: 17515370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner.
    Kuo YT; Li CW; Chen CY; Jao J; Wu DK; Liu GC
    J Magn Reson Imaging; 2004 May; 19(5):598-604. PubMed ID: 15112309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignancy assessment of brain tumours with magnetic resonance spectroscopy and dynamic susceptibility contrast MRI.
    Fayed N; Dávila J; Medrano J; Olmos S
    Eur J Radiol; 2008 Sep; 67(3):427-33. PubMed ID: 18442889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of choline and pharmacokinetic parameters in breast cancer measured by MR spectroscopic imaging and dynamic contrast enhanced MRI.
    Su MY; Baik HM; Yu HJ; Chen JH; Mehta RS; Nalcioglu O
    Technol Cancer Res Treat; 2006 Aug; 5(4):401-10. PubMed ID: 16866570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization of musculoskeletal tumors by proton MR spectroscopy.
    Fayad LM; Barker PB; Bluemke DA
    Semin Musculoskelet Radiol; 2007 Sep; 11(3):240-5. PubMed ID: 18260034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study.
    Bartella L; Morris EA; Dershaw DD; Liberman L; Thakur SB; Moskowitz C; Guido J; Huang W
    Radiology; 2006 Jun; 239(3):686-92. PubMed ID: 16603660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.